Hepatitis

A Steroid-Sparing Breakthrough(Obexelimab) for IgG4-Related Disease: NEJM | June 2026

Introduction: IgG4-related disease (IgG4-RD) is a chronic fibroinflammatory disorder that can affect virtually any organ. Although glucocorticoids remain the mainstay of treatment, relapse is common after tapering, and long-term steroid toxicity remains a major concern. The INDIGO trial evaluated obexelimab, a novel B-cell modulator, as a steroid-sparing therapy. Why was this study needed? Relapse is common after glucocorticoid withdrawal in IgG4-RD. Long-term corticosteroid therapy is associated with substantial toxicity. Effective steroid-sparing therapies are limited. Conventional B-cell depletion has safety and relapse concerns. Novel targeted therapies are needed to maintain durable remission. Results: Obexelimab significantly reduced disease flares, prolonging flare-free survival compared with placebo over 52 weeks. Patients receiving obexelimab achieved higher complete remission rates while requiring substantially less rescue glucocorticoid therapy. Obexelimab was well tolerated, with fewer serious adverse events than placebo despite mild increases in arthralgia, hypersensitivity, and diarrhea. Clinical Impact: The INDIGO trial establishes obexelimab as the first phase III biologic to demonstrate robust steroid-sparing efficacy in IgG4-related disease. Unlike conventional B-cell-depleting therapies, obexelimab modulates B-cell activity without depleting B cells, offering a novel therapeutic approach with the potential to reduce long-term corticosteroid exposure. Bottom Line: Obexelimab represents a major therapeutic advance for IgG4-related disease. It significantly reduces disease flares, increases sustained remission, and minimizes glucocorticoid exposure, making it a promising new targeted treatment for this chronic multisystem disorder.

HBV Reactivation During Immunosuppressive Therapy: Alimentary Pharmacology & Therapeutics | July 2026

Introduction: Hepatitis B virus (HBV) reactivation remains a potentially serious complication of immunosuppressive and anticancer therapies. While current guidelines classify patients into high-, moderate-, and low-risk categories, this editorial discusses new real-world evidence suggesting that HBV reactivation risk is more dynamic than previously appreciated. Key Takeaways: Current HBV risk stratification remains broadly valid, with anti-CD20 therapies continuing to carry the highest risk of HBV reactivation. Clinically meaningful HBV reactivation can still occur in patients considered "low risk," particularly those receiving low-dose or short-term corticosteroids. HBV risk is dynamic rather than binary, influenced by cumulative immunosuppression, combination therapies, host factors, and monitoring intensity. Tyrosine kinase inhibitors, anthracyclines, and several targeted therapies also demonstrated clinically relevant HBV reactivation risk. Even with regular HBV DNA monitoring, some patients progressed to hepatitis, highlighting the limitations of surveillance alone. The findings renew the debate over HBV DNA monitoring versus universal antiviral prophylaxis, especially in patients receiving prolonged or multidrug immunosuppressive therapy. Treatment decisions should consider the overall immunosuppressive burden rather than relying solely on individual drug-risk categories. Clinical Impact: This editorial reinforces current guideline recommendations while emphasizing that "low risk" should never be interpreted as "no risk." Careful HBV screening, individualized risk assessment, close monitoring, and timely antiviral prophylaxis remain essential for patients receiving immunosuppressive therapy. Bottom Line: HBV reactivation risk exists across the entire spectrum of immunosuppressive therapy. Rather than depending solely on static drug-based categories, clinicians should adopt a dynamic, patient-centered approach that accounts for cumulative immunosuppression and individual risk factors.

Advancing Liver Health in a Shifting Global Landscape: Nat Re Gastro & Hepatol | July 2026

Introduction: Liver disease is entering a new era. While steatotic liver disease (SLD) is rapidly becoming one of the world's leading non-communicable diseases, progress toward viral hepatitis elimination has slowed. This editorial highlights the urgent need for coordinated global strategies to improve liver health and reduce inequities in prevention, diagnosis, and care. Key Takeaways: The World Health Assembly has officially recognized steatotic liver disease (SLD) as a major non-communicable disease, marking a historic milestone for global liver health. MASLD affects an estimated 1.3 billion people worldwide, with the global burden expected to increase substantially by 2050. MetALD (Metabolic and Alcohol-Related Liver Disease) is increasingly recognized as an important contributor to liver-related morbidity, particularly in Europe. Despite progress, viral hepatitis remains a major global health challenge, and the WHO 2030 elimination targets are unlikely to be achieved without stronger implementation. Encouragingly, new HBV infections and hepatitis C-related deaths continue to decline, reflecting the impact of vaccination and antiviral therapies. Healthcare inequities, limited access to prevention and treatment, and armed conflicts remain major barriers to improving liver health worldwide. Integrating liver disease into national non-communicable disease (NCD) strategies is essential to reduce liver-related mortality, hepatocellular carcinoma, and cardiometabolic complications. Clinical Impact: This editorial emphasizes that liver health should no longer be viewed in isolation. Prevention of MASLD, alcohol-related liver disease, viral hepatitis, and liver cancer requires coordinated public health policies, equitable access to care, and integration into broader cardiometabolic and NCD programs. Bottom Line: Global liver health is at a turning point. While recognition of steatotic liver disease as a major NCD represents a landmark achievement, accelerating prevention, expanding access to care, and reducing global health inequities will be critical to lowering the future burden of liver disease.

ML Predicts Response to TPE in Pediatric ALF: JCEH | July 2026

Introduction: Therapeutic plasma exchange (TPE) is increasingly used in pediatric acute liver failure (ALF), but it artificially lowers bilirubin and INR, making it difficult to determine whether a child is truly improving or requires urgent liver transplantation. This study developed machine learning (ML) models to predict response to TPE and support real-time clinical decision-making. Why was this study needed? TPE alters conventional prognostic markers, complicating transplant decisions. Reliable early predictors of TPE response are lacking. Delayed recognition of treatment failure may adversely affect survival. Machine learning may improve individualized risk prediction. A real-time clinical decision support tool could enhance patient management. Results: Machine learning models accurately predicted response to TPE, with the best performance 12–18 hours after the first TPE session, allowing early identification of responders and non-responders. Logistic Regression, Support Vector Machine (SVM), and XGBoost showed the highest predictive performance, consistently outperforming other ML models. These validated models were integrated into a web-based clinical decision support tool, enabling real-time prediction of TPE response to assist liver transplant decision-making. Clinical Impact: This study demonstrates that artificial intelligence can support critical decision-making in pediatric acute liver failure by identifying children unlikely to respond to TPE at an early stage. Such tools may help optimize transplant timing while avoiding unnecessary delays in life-saving treatment. Bottom Line: Machine learning can accurately predict response to therapeutic plasma exchange in pediatric acute liver failure. A simple web-based prediction tool may assist clinicians in determining which children are likely to recover with TPE and which may require urgent liver transplantation.

Alcohol Intake and Health Study: J of Studies on Alcohol and Drugs | July 2026

Introduction: For decades, low-to-moderate alcohol consumption has been considered by some to offer potential cardiovascular benefits. This comprehensive U.S. modeling study re-evaluated the lifetime health impact of alcohol consumption using contemporary cause-specific data on alcohol-related diseases and injuries. Why was this study needed? Current drinking recommendations remain controversial because many previous studies suggested a protective effect of moderate alcohol intake. Updated evidence was needed to quantify the lifetime risks associated with different drinking levels and patterns. What did the study show? No overall protective health benefit was observed, even at low levels of alcohol consumption. Alcohol-related mortality and morbidity increased progressively with increasing weekly alcohol intake. Lifetime alcohol-attributable mortality exceeded 1 in 1,000 at approximately 7 drinks per week. At around 8–9 drinks per week, the lifetime risk increased to more than 1 in 100. Men consuming 14 drinks per week had an estimated 1 in 25 (4%) lifetime risk of dying from an alcohol-attributable cause. Drinking more than one drink per occasion further increased the risks of breast cancer, cardiovascular disease, and injuries. The findings support limiting alcohol intake to no more than one standard drink per day for both men and women. Clinical Impact: These findings challenge the long-held perception that moderate alcohol consumption is beneficial. Clinicians should counsel patients that alcohol-related health risks begin at relatively low levels of intake and increase further with higher weekly consumption and binge drinking patterns. Take-Home Message: This large U.S. study found no net health benefit from low-to-moderate alcohol consumption. Alcohol-related health risks rise progressively with increasing intake, supporting a simple public health message: less alcohol is better, and if consumed, intake should ideally be limited to one drink or less per day.

Genetic Testing in Adult Cholestatic Liver Disease: Gut | June 2026

Introduction: Advances in genetic sequencing have transformed the understanding of cholestatic liver diseases. Conditions once considered exclusive to children are now recognized in adolescents and adults, with genetic variants increasingly explaining unexplained cholestasis, recurrent pruritus, and gallstone disease. Why was this review needed? The widespread availability of affordable genetic testing has uncovered pathogenic variants in adults with cholestatic liver disease. Identifying these variants has important implications for diagnosis, prognosis, family screening, and selection of emerging targeted therapies. What did the review show? Adult cholestatic disorders frequently harbor pathogenic variants in ABCB4, ABCB11, and ATP8B1, the same genes implicated in PFIC. Genetic cholestasis encompasses a broad spectrum, including PFIC, benign recurrent intrahepatic cholestasis (BRIC), intrahepatic cholestasis of pregnancy (ICP), and low phospholipid-associated cholelithiasis (LPAC). Genetic testing should be considered in adults with unexplained cholestasis, recurrent cholestatic episodes, severe pruritus, early gallstone disease, or a positive family history. Identifying the underlying mutation enables more personalized treatment using ursodeoxycholic acid, IBAT inhibitors, or other targeted therapies. IBAT inhibitors have shown significant benefit in relieving cholestatic pruritus and may have an expanding role beyond pediatric PFIC. Genetic diagnosis also facilitates genetic counseling, family screening, and improved long-term disease management. Clinical Impact: Genetic evaluation is becoming an essential component of adult cholestatic liver disease rather than a test reserved for rare pediatric disorders. Integrating genomic information into routine hepatology practice enables earlier diagnosis and more individualized therapy. Take-Home Message: Adult cholestatic liver disease is increasingly recognized as a spectrum of inherited disorders. Genetic testing can identify the underlying cause, guide precision treatment, and improve patient outcomes, making genomics an integral part of modern hepatology.

Genetic Testing in Adult Cholestatic Liver Disease: Gut | July 2026

Introduction: Advances in genetic sequencing have transformed the understanding of cholestatic liver diseases. Conditions once considered exclusive to children are now recognized in adolescents and adults, with genetic variants increasingly explaining unexplained cholestasis, recurrent pruritus, and gallstone disease. Why was this review needed? The widespread availability of affordable genetic testing has uncovered pathogenic variants in adults with cholestatic liver disease. Identifying these variants has important implications for diagnosis, prognosis, family screening, and selection of emerging targeted therapies. What did the review show? Adult cholestatic disorders frequently harbor pathogenic variants in ABCB4, ABCB11, and ATP8B1, the same genes implicated in PFIC. Genetic cholestasis encompasses a broad spectrum, including PFIC, benign recurrent intrahepatic cholestasis (BRIC), intrahepatic cholestasis of pregnancy (ICP), and low phospholipid-associated cholelithiasis (LPAC). Genetic testing should be considered in adults with unexplained cholestasis, recurrent cholestatic episodes, severe pruritus, early gallstone disease, or a positive family history. Identifying the underlying mutation enables more personalized treatment using ursodeoxycholic acid, IBAT inhibitors, or other targeted therapies. IBAT inhibitors have shown significant benefit in relieving cholestatic pruritus and may have an expanding role beyond pediatric PFIC. Genetic diagnosis also facilitates genetic counseling, family screening, and improved long-term disease management. Clinical Impact: Genetic evaluation is becoming an essential component of adult cholestatic liver disease rather than a test reserved for rare pediatric disorders. Integrating genomic information into routine hepatology practice enables earlier diagnosis and more individualized therapy. Take-Home Message: Adult cholestatic liver disease is increasingly recognized as a spectrum of inherited disorders. Genetic testing can identify the underlying cause, guide precision treatment, and improve patient outcomes, making genomics an integral part of modern hepatology.

ELF and Liver Disease: Gut | May 2026

Introduction: Early detection of advanced fibrosis in steatotic liver disease remains a major clinical challenge, particularly in individuals with type 2 diabetes and hazardous alcohol use. This real-world UK study evaluated the role of the Enhanced Liver Fibrosis (ELF) test as a community screening tool to identify patients requiring further assessment with liver stiffness measurement (LSM). Why was this study needed? Current liver disease is often diagnosed at an advanced stage when treatment options are limited. Simple, non-invasive screening strategies are needed to identify high-risk individuals earlier and facilitate timely intervention. What did the study show? Nearly 1,000 high-risk individuals from diabetes and alcohol services underwent ELF testing in routine clinical practice. Most patients had low ELF scores, avoiding unnecessary referral for further liver assessment. Patients with diabetes had higher ELF scores than those with hazardous alcohol use. Among patients undergoing LSM, advanced fibrosis was considerably more common in the alcohol cohort than in the diabetes cohort. The study highlights that ELF alone may not identify all patients with advanced liver disease, particularly in alcohol-related liver disease. Combining ELF with liver stiffness measurement improves the detection of clinically significant fibrosis in at-risk populations. Clinical Impact: This study supports the use of the ELF test as an effective first-line, community-based screening tool for patients with diabetes or hazardous alcohol use. However, interpretation should be tailored to the underlying liver disease, and sequential testing with transient elastography may improve diagnostic accuracy. Take-Home Message: The ELF test is a practical non-invasive screening tool for identifying advanced liver disease in high-risk populations. When combined with liver stiffness measurement, it can improve early detection of clinically significant fibrosis and support timely referral for specialist care.

The Liver as a Target for Healthy Aging : Ageing Res Rev | June 2026

Introduction: Aging is a complex biological process that affects multiple organs and progressively increases vulnerability to chronic diseases. Among these organs, the liver occupies a central role in maintaining systemic homeostasis through regulation of glucose and lipid metabolism, nutrient storage, protein synthesis, immune surveillance, and detoxification. Increasing evidence suggests that age-related changes in hepatic function extend beyond the liver itself and may influence the aging trajectory of the entire organism. Problem Statement: While longevity research has traditionally focused on pathways within the nervous, cardiovascular, and musculoskeletal systems, the liver has received comparatively less attention as a therapeutic target for healthy aging. Understanding how liver aging contributes to systemic decline and age-related diseases may reveal novel interventions capable of improving lifespan and healthspan. Summary: This review highlights the liver as a critical regulator of systemic aging and explores how liver-targeted interventions may promote longevity. The authors describe how aging progressively impairs hepatic metabolic flexibility, detoxification capacity, regenerative potential, and immune regulation. These changes increase susceptibility to metabolic dysfunction, chronic inflammation, and tissue injury, which can subsequently influence the function of distant organs through complex interorgan communication networks. The review synthesizes emerging evidence showing that modulation of key hepatic pathways involved in nutrient sensing, mitochondrial function, cellular senescence, oxidative stress, inflammation, and metabolic regulation may slow biological aging. Importantly, many established longevity interventions—including caloric restriction, exercise, and pharmacologic approaches targeting metabolic pathways—appear to exert part of their beneficial effects through actions on the liver. The authors propose that preserving liver health may represent an effective strategy for reducing the burden of age-related diseases, including metabolic disorders, cardiovascular disease, neurodegeneration, and cancer. Beyond its traditional role as a metabolic organ, the liver is increasingly recognized as a central coordinator of whole-body aging processes. This review provides a compelling framework supporting liver-directed therapies as a promising avenue for extending healthspan and promoting healthy aging, while highlighting the need for further translational research to identify clinically applicable liver-targeted longevity interventions.

Bezafibrate Shows Meaningful Long-Term Benefit in PBC : J Hepatol | June 2026

Introduction: Ursodeoxycholic acid (UDCA) remains the first-line treatment for primary biliary cholangitis (PBC), yet a substantial proportion of patients fail to achieve complete biochemical response. Persistent elevation of alkaline phosphatase (ALP) after UDCA therapy is associated with increased risks of liver transplantation and liver-related mortality. Bezafibrate has emerged as an effective adjunctive therapy in patients with incomplete biochemical response, but its clinical benefit has often been reported using relative risk measures that can be difficult to interpret in routine practice. Problem Statement: While previous studies have demonstrated favorable effects of bezafibrate on biochemical markers and long-term outcomes, clinicians require more clinically meaningful measures to understand the magnitude of benefit. The number needed to treat (NNT) provides an intuitive assessment of how many patients need treatment to prevent major clinical events such as transplantation or death. Summary: This study evaluated the projected clinical benefit of bezafibrate in patients with PBC who continued to have elevated ALP levels despite UDCA therapy. Using data from a large national PBC cohort and previously validated treatment-effect estimates, the investigators calculated the number needed to treat to prevent liver transplantation or death. The analysis demonstrated a substantial long-term benefit of bezafibrate, with relatively few patients requiring treatment to prevent one major adverse liver outcome. Importantly, the benefit became more pronounced over longer follow-up periods and was greatest among patients with higher residual ALP levels, reflecting their increased baseline risk. However, clinically meaningful benefits were also observed in patients with only modest ALP elevation after one year of UDCA treatment, suggesting that the therapeutic value of bezafibrate extends beyond traditionally high-risk populations. These findings provide a practical perspective on the magnitude of benefit associated with bezafibrate and strengthen the rationale for its use as an adjunctive therapy in patients with incomplete biochemical response to UDCA. From a clinical standpoint, the results support earlier consideration of bezafibrate in appropriate patients and highlight its potential to reduce progression to liver transplantation and liver-related mo

MELD Exceptions in PSC Under Scrutiny : Liver Transpl | June 2026

Introduction: Primary sclerosing cholangitis (PSC) is a chronic cholestatic liver disease that frequently progresses to liver failure, recurrent bacterial cholangitis, and the need for liver transplantation. Because the Model for End-Stage Liver Disease (MELD) score may not fully capture the disease burden experienced by some patients with PSC, exception policies have been developed to provide additional transplant priority in selected circumstances. However, the appropriateness and effectiveness of these exceptions remain an area of ongoing debate. Problem Statement: MELD exception policies are intended to address clinical situations in which standard MELD scores underestimate transplant urgency. In PSC, exceptions have often been granted for recurrent cholangitis and other disease-related complications, yet the supporting evidence has been limited and inconsistent. Determining whether these policies accurately identify patients with increased mortality risk or improved transplant benefit is essential to maintaining fairness in organ allocation. Summary: This editorial examines the current practice of granting MELD exception points for patients with PSC and questions whether existing policies are sufficiently supported by robust clinical evidence. The authors highlight a central challenge in transplant allocation: balancing the need to recognize PSC-specific complications while ensuring equitable organ distribution across all liver disease populations. Although recurrent bacterial cholangitis and related complications can significantly impair quality of life and contribute to morbidity, evidence linking these events to a clearly increased waitlist mortality risk remains limited. The editorial argues that exception policies should be driven by objective data demonstrating measurable transplant benefit rather than historical practice patterns or expert consensus alone. The authors emphasize the need for contemporary outcome-based studies that evaluate waitlist mortality, post-transplant outcomes, and the true impact of PSC-related complications on patient prognosis. As transplant medicine increasingly moves toward evidence-based allocation systems, reassessment of PSC exception policies may be necessary to ensure fairness, transparency, and optimal use of scarce donor organs. The article ultimately calls for stronger data to guide future policy decisions and to determine whether current MELD exception practices for PSC remain justified in modern liver transplantation.

Precision HBV Care Moves Toward Functional Cure : Frontline Gastroenterology | May 2026

Introduction Chronic Hepatitis B remains a leading global cause of cirrhosis and Hepatocellular Carcinoma despite the availability of potent antiviral therapy. However, management strategies are rapidly evolving from simple viral suppression toward precision, biomarker-driven care focused on long-term disease modification and functional cure. Problem Statement Traditional hepatitis B management has relied heavily on alanine aminotransferase levels and HBV DNA thresholds, which may fail to identify patients at ongoing risk of fibrosis progression and hepatocellular carcinoma, particularly those with concurrent metabolic dysfunction. Summary This contemporary review highlights the major clinical and conceptual advances incorporated into the 2025 European Association for the Study of the Liver hepatitis B guidance, outlining a shift toward earlier treatment, integrated metabolic assessment and personalized biomarker-led management. A central theme is the movement toward achieving “functional cure,” defined by sustained loss of hepatitis B surface antigen with durable viral suppression. This represents a major evolution from the previous strategy of indefinite viral suppression alone. The review emphasizes that patients with concurrent Metabolic Dysfunction-Associated Steatotic Liver Disease may experience fibrosis progression even in the setting of low viral replication or normal liver enzymes. This recognition substantially broadens the clinical framework for treatment decision-making. Novel viral biomarkers are increasingly reshaping hepatitis B management. Quantitative HBsAg, hepatitis B core-related antigen and HBV RNA are emerging as clinically important tools for refining disease phase classification, predicting treatment response and identifying patients suitable for safe therapy discontinuation. These biomarkers may also help identify patients with lower intrahepatic viral transcriptional activity who are closer to achieving immune control. Importantly, the review highlights that hepatitis B is no longer viewed solely as a virological disease but increasingly as a complex interaction between viral activity, host immunity, fibrosis biology and metabolic dysfunction. The updated paradigm supports earlier antiviral initiation in selected patients before advanced fibrosis develops, reflecting growing evidence that cumulative inflammatory injury drives long-term hepatocarcinogenesis. Special populations receive significant attention, including pregnant individuals, patients receiving immunosuppressive therapy and those with Hepatitis D co-infection, where tailored management strategies are essential. The review also highlights emerging minimally invasive liver fine needle aspiration approaches that allow intrahepatic immune and virological profiling. These technologies may accelerate development of individualized immunotherapeutic and antiviral strategies. Clinically, this transition mirrors broader trends in hepatology toward precision medicine, where treatment decisions increasingly integrate virological, metabolic, immunologic and fibrosis-related data rather than relying on isolated laboratory thresholds. The article is particularly relevant because current nucleos(t)ide analogues rarely achieve HBsAg loss, creating strong interest in finite-treatment and immune-restorative strategies. Several investigational therapeutic approaches are discussed indirectly within this evolving framework, including siRNA therapies, capsid assembly modulators, therapeutic vaccines and immune checkpoint-targeting approaches designed to restore antiviral immunity. The review additionally underscores the importance of improving screening and linkage-to-care pathways, especially in migrant and underserved populations where hepatitis B burden remains concentrated. Limitations remain substantial. Many emerging biomarkers are not yet globally standardized, treatment cessation strategies remain incompletely validated and access to advanced testing varies considerably across healthcare systems. Future hepatitis B care will likely involve integrated risk prediction models combining viral biomarkers, metabolic phenotyping, fibrosis assessment and immune profiling to individualize treatment intensity and duration. Overall, this review captures a major transition in chronic hepatitis B management—from static viral suppression algorithms toward biomarker-guided precision hepatology focused on earlier intervention, individualized monitoring and ultimately functional cure.

PLEX Shows Limited Overall Benefit in HAV-ALF : Indian J Gastroenterol | May 2026

Introduction Acute Liver Failure caused by Hepatitis A remains an important cause of mortality in young adults in developing countries. Although Therapeutic Plasma Exchange has shown benefit in acute liver failure overall, disease-specific evidence in hepatitis A virus-related ALF has been lacking. Problem Statement The role of plasma exchange in HAV-related acute liver failure remains uncertain, particularly regarding patient selection and hemodynamic status. Existing data are limited, and it is unclear whether all patients benefit equally from extracorporeal support strategies. Summary This large Indian multicenter cohort study evaluated the real-world effectiveness of plasma exchange compared with standard medical treatment in patients with hepatitis A-related acute liver failure across 13 tertiary centers. The study included more than 230 patients, making it one of the largest HAV-ALF cohorts evaluating plasma exchange to date. Overall in-hospital native liver survival did not significantly differ between patients treated with plasma exchange and those receiving standard medical therapy alone. This finding suggests that routine universal application of plasma exchange in all HAV-ALF patients may not improve outcomes. However, an important signal emerged in a clinically relevant subgroup. Among hemodynamically stable patients not requiring inotropes, survival appeared substantially better in the plasma exchange cohort on univariate analysis. This observation is biologically plausible because patients without advanced circulatory collapse may better tolerate extracorporeal therapy and may still possess reversible hepatic injury amenable to supportive immune and toxin-modulating interventions. Nevertheless, the survival advantage was not maintained after propensity score matching and regression adjustment, indicating potential selection bias and residual confounding within this retrospective dataset. The findings therefore suggest that hemodynamic stability may be an important determinant of response to plasma exchange rather than plasma exchange being universally beneficial across all HAV-ALF phenotypes. Clinically, the study highlights the heterogeneity of acute liver failure and reinforces the need for individualized extracorporeal support strategies rather than protocolized blanket therapy. The work is particularly relevant in the Indian setting, where hepatitis A continues to contribute significantly to acute liver failure burden and transplant access remains limited. Importantly, the cohort also included patients fulfilling King's College Criteria, reflecting inclusion of severe disease presentations encountered in real-world hepatology practice. The study further raises important questions regarding optimal timing, patient selection and intensity of plasma exchange in viral acute liver failure. Potential mechanisms of benefit may include reduction of inflammatory mediators, removal of circulating toxins, correction of coagulopathy and temporary support of systemic homeostasis during hepatic recovery. However, advanced multiorgan dysfunction and vasoplegia may limit the efficacy of extracorporeal support once systemic decompensation becomes established. The retrospective design, inter-center variability and non-randomized treatment allocation remain important limitations. Additionally, differences in disease severity and referral patterns may have influenced treatment selection. Future prospective randomized studies focused specifically on hemodynamically stable HAV-ALF populations are needed to clarify whether an early “window of opportunity” exists where plasma exchange can alter native liver survival. The findings also support development of more refined prognostic models integrating hemodynamic status, inflammatory biomarkers and dynamic organ failure assessment to guide extracorporeal therapy decisions. Overall, this multicenter Indian study suggests that plasma exchange does not improve survival across all patients with hepatitis A-related acute liver failure, but it may offer benefit in carefully selected hemodynamically stable patients who are not yet requiring inotropic support.

Bepirovirsen Achieves Functional Cure in Chronic Hepatitis B: NEJM | May 2026

Bepirovirsen is an antisense oligonucleotide that targets HBV transcripts, aiming to reduce viral proteins and achieve a functional cure rather than lifelong viral suppression. In two large Phase 3 trials (B-Well 1 and B-Well 2), approximately 20% of treated patients achieved functional cure, compared with 0% in the placebo group. Functional cure was defined as sustained HBV DNA suppression below the limit of quantification together with HBsAg loss, maintained for at least 24 weeks after treatment. The results were highly consistent across both studies, with cure rates of 20% in B-Well 1 and 19% in B-Well 2, providing strong validation of the treatment effect. All patients were receiving stable nucleos(t)ide analogue therapy at study entry, and antiviral therapy was subsequently discontinued, demonstrating the potential for finite-duration treatment. The study provides some of the strongest evidence to date that chronic HBV infection can be functionally cured without indefinite antiviral therapy. Adverse events were more common with bepirovirsen than placebo. The most frequent significant adverse event was ALT elevation, which may reflect immune-mediated clearance of infected hepatocytes. Serious adverse events were relatively uncommon, occurring in 7% of bepirovirsen-treated patients compared with 4% of placebo-treated patients. Although highly encouraging, approximately 80% of patients did not achieve functional cure, indicating that further improvements are still needed. Bepirovirsen is likely to become an important component of future combination cure strategies, potentially alongside siRNA therapies, therapeutic vaccines, and immune modulators. The trial represents a major milestone in HBV therapeutics and moves the field closer to the long-sought goal of a practical and scalable cure for chronic hepatitis B. Bottom Line: Bepirovirsen is the first antisense oligonucleotide to demonstrate Phase 3 functional cure rates of approximately 20% in chronic hepatitis B, marking one of the most important advances in HBV treatment in the past decade.

High Placebo Response Rates Continue to Challenge MASH Drug Trials : Clinical Gastroenterology and Hepatology | May 2026

Introduction Metabolic dysfunction–associated steatohepatitis (MASH) has become a major global liver disease burden and a central focus of therapeutic development. Despite intense pharmaceutical activity and numerous late-phase clinical trials, demonstrating meaningful histologic improvement remains challenging, partly because placebo groups frequently exhibit substantial spontaneous or treatment-associated improvement. Problem Statement Elevated placebo response rates complicate interpretation of MASH clinical trials by reducing apparent treatment effect size and increasing the risk of failed endpoints despite biologically active therapies. The extent and determinants of placebo responses across modern MASH trials remain poorly characterized, limiting optimal trial design and endpoint selection. Summary This large systematic review and meta-analysis demonstrates that placebo responses in MASH trials are both substantial and highly variable depending on the endpoint evaluated. Approximately one in ten placebo-treated noncirrhotic patients achieved histologic MASH resolution without fibrosis worsening, while meaningful reductions in hepatic fat content and alanine aminotransferase normalization were also frequently observed in placebo arms. Importantly, the analysis found no consistent patient or study-level factors that reliably predicted placebo response, emphasizing the inherent complexity and heterogeneity of MASH trial populations. These findings reinforce that lifestyle modification, behavioral changes triggered by trial participation and the fluctuating natural history of metabolic liver disease likely contribute significantly to placebo-associated improvement. The study also highlights that placebo effects differ across histologic, biochemical and imaging endpoints, suggesting that endpoint selection critically influences perceived therapeutic efficacy in MASH drug development. Overall, this analysis provides important context for interpreting contemporary MASH trials and underscores the need for improved trial design strategies, including more precise patient phenotyping, optimized endpoint selection and potentially longer study durations to better distinguish true drug efficacy from background placebo-associated improvement.

Hepatitis B Vaccination: A Success Story - Gastroenterology | March 26

Introduction Hepatitis B virus (HBV) infection remains a major global health threat, with an estimated 254 million people living with chronic infection and more than 1.1 million deaths annually from cirrhosis and hepatocellular carcinoma (HCC). Because HBV infection acquired in infancy carries up to a 90% risk of chronic infection, prevention through vaccination—particularly the birth dose—has become the cornerstone of global elimination strategies. Summary This commentary highlights the profound public health impact of hepatitis B vaccination and underscores the need to sustain universal infant immunization. Since the introduction of HBV vaccines in the 1980s, global vaccination programs have prevented millions of infections and deaths. Universal infant vaccination, including a birth dose within 24 hours, has been especially transformative. Taiwan’s national program reduced chronic HBV prevalence from 10% in 1984 to 0.5% by 2019 and significantly lowered childhood hepatocellular carcinoma incidence. Globally, vaccination has reduced HBsAg prevalence among children under five years from approximately 5% to below 1%, preventing an estimated 22 million deaths. Hepatitis B vaccines are among the safest and most effective vaccines ever developed, with over one billion doses administered worldwide and protective immunity lasting more than three decades. The combination of maternal screening, birth dose vaccination, hepatitis B immunoglobulin for exposed infants, and antiviral therapy during pregnancy can prevent up to 99% of mother-to-child transmission. Despite these successes, challenges remain. Global birth-dose coverage is only about 46%, with particularly low uptake in Africa. In addition, policy debates in some countries about delaying infant vaccination risk reversing decades of progress. The authors emphasise that universal birth-dose vaccination is the most effective and cost-efficient strategy to eliminate HBV transmission and prevent future liver disease and cancer. Sustaining and expanding vaccination coverage is essential to achieving global hepatitis B elimination goals.

Prognostic value of LSM in PBC- AJG Feb.26

Risk stratification in primary biliary cholangitis (PBC) traditionally relies on biochemical response to ursodeoxycholic acid, but liver stiffness measurement (LSM) is increasingly used to assess fibrosis and portal hypertension. In everyday practice, clinicians often encounter a dilemma: biochemistry and LSM do not always move in the same direction, and it has been unclear how to interpret these discordant results. This large international multicenter study clarifies that uncertainty. The investigators evaluated patients with PBC who had serial LSM assessments and no prior hepatic decompensation, transplant, or liver cancer. They examined how biochemical response and changes in LSM relate to future liver-related outcomes, with a particular focus on discordant patterns. The key finding is that discordance between biochemical response and LSM is common, occurring in more than half of patients. Importantly, when discordance exists, the most recent LSM value is the strongest predictor of future liver-related events, including first hepatic decompensation. Once the current LSM is known, earlier LSM trends and biochemical response add little additional prognostic information. Patients who achieved biochemical response but had a persistently elevated current LSM remained at high risk of adverse liver outcomes. Conversely, patients with biochemical nonresponse but a low current LSM had a comparatively lower risk. This indicates that fibrosis burden and portal pressure—reflected by LSM—ultimately outweigh biochemical normalisation in determining prognosis. From a practical standpoint, this study simplifies clinical decision-making. Rather than integrating complex trajectories of past LSM values and biochemical fluctuations, clinicians can focus on the latest reliable LSM to guide surveillance intensity, timing of second-line therapy, and transplant referral discussions. In summary, while both biochemistry and LSM are important in PBC, the current LSM is the dominant prognostic marker. This finding supports routine, longitudinal elastography and emphasises that biochemical response alone does not guarantee low long-term risk in PBC.

How Alcohol Acts as a ‘Second Hit’ in HBV-Driven Liver Cancer- AJG Feb.26

Introduction Hepatocellular carcinoma (HCC) commonly arises from chronic liver injury due to hepatitis B virus (HBV), alcohol use, metabolic dysfunction, or combinations of these factors. While each risk factor independently promotes carcinogenesis, how alcohol synergises with HBV to accelerate tumor development has remained incompletely understood. This study addresses that gap by identifying a novel metabolic and lysosomal pathway through which alcohol acts as a powerful “second hit” in HBV-driven HCC. What the study shows Using HBx-transgenic mouse models of spontaneous HBV-related hepatocarcinogenesis, the authors demonstrate that chronic alcohol exposure markedly accelerates HCC development. Mechanistically, alcohol induces endoplasmic reticulum (ER) stress, activating the transcription factor ATF4. ATF4 directly upregulates lysosomal phospholipase A2 (LPLA2), an enzyme that drives accumulation of bis(monoacylglycero)phosphate (BMP)—a lipid enriched in lysosomes. BMP accumulation stabilises lysosomal membranes, helping tumour cells survive under metabolic and oxidative stress. At the same time, increased BMP activates MAPK/ERK signalling, promoting hepatocyte proliferation and tumor growth. Silencing LPLA2 or enzymes involved in BMP synthesis blunted alcohol-driven tumor growth and restored apoptotic sensitivity. Why this matters clinically 1) Explains synergy between HBV and alcohol This work provides a biologically coherent explanation for why alcohol consumption dramatically worsens outcomes in HBV-infected patients, beyond additive toxicity. 2) Highlights lipid–lysosomal metabolism as a cancer driver Rather than focusing solely on DNA damage, this study emphasises metabolic reprogramming and lysosomal adaptation as key oncogenic processes in HCC. 3) Identifies actionable targets LPLA2 and BMP metabolism emerge as potential: therapeutic targets, and prognostic biomarkers, especially in patients with combined HBV and alcohol exposure. 4) Reinforces the clinical importance of alcohol abstinence in HBV The findings offer strong mechanistic support for strict alcohol avoidance in HBV-infected individuals—not just for fibrosis prevention, but for cancer risk reduction. Limitations and open questions Animal models cannot fully replicate human HBV–alcohol interactions. Whether this pathway also drives fibrosis or HCC in non-HBV liver diseases remains unclear. Long-term safety of targeting LPLA2/BMP pathways needs careful evaluation. Bottom-line takeaway from GastroAGI Alcohol potentiates HBV-related hepatocarcinogenesis through an ER stress–driven, lipid–lysosomal survival pathway involving LPLA2 and BMP. This work strengthens the biological rationale for alcohol abstinence in HBV and identifies new metabolic vulnerabilities in HCC. One-line GastroAGI takeaway In HBV infection, alcohol is not just an additive—it is a molecular accelerator of liver cancer.

EUS-guided liver biopsy – a novel technique (GIE, Jan-2026)

### Indications of EUS-Guided Liver Biopsy EUS-guided liver biopsy (EUS-LB) is increasingly utilized as a minimally invasive technique for obtaining liver tissue samples. Common indications for EUS-LB include: 1. Evaluation of unexplained liver abnormalities, such as elevated liver enzymes or abnormal imaging findings. 2. Diagnosis and staging of liver diseases, including nonalcoholic fatty liver disease (NAFLD), autoimmune hepatitis, and cirrhosis. 3. Assessment of focal liver lesions to distinguish benign from malignant pathology. 4. Sampling in patients with challenging anatomies or high risk for adverse events associated with percutaneous or transjugular liver biopsy. ### Difference Between 22-Gauge and 19-Gauge Needles The gauge of the needle used during EUS-LB significantly impacts specimen quality and procedural outcomes: 1. **19-Gauge Needle**: - Traditionally preferred for EUS-LB due to its ability to obtain larger tissue samples with higher adequacy rates. - Provides specimens with longer aggregate length and higher counts of complete portal tracts (CPTs), which are critical for accurate pathological evaluation. - Associated with higher rates of blood contamination and may pose a greater risk of adverse events, particularly in patients with challenging anatomies. 2. **22-Gauge Needle**: - Historically considered inferior due to smaller sample sizes and lower adequacy rates compared to 19-gauge needles. - Emerging evidence suggests that the use of novel techniques, such as hydrostatic sampling, can improve performance and tissue adequacy, making 22-gauge needles a viable option. - Offers advantages in patients with high-risk profiles or difficult anatomical considerations due to its smaller size and reduced invasiveness. ### Hydrostatic Sampling Technique (HST) The hydrostatic sampling technique (HST) is a novel method that enhances the quality of tissue samples obtained during EUS-LB. Key features include: 1. Improved tissue adequacy: In the study provided, the HST achieved high adequacy rates (≥93%) for both 22-gauge and 19-gauge needles, meeting clinical standards. 2. Reduced blood contamination: The 22-gauge HST demonstrated significantly less blood contamination compared to both 19-gauge HST and wet suction (WS). 3. Comparable performance to traditional techniques: The HST allows 22-gauge needles to achieve similar specimen adequacy as 19-gauge needles, making it a promising option for patients at high risk for procedural complications. ### Conclusion The findings in the study suggest that the hydrostatic sampling technique is a significant advancement in EUS-guided liver biopsy. Specifically: 1. The HST enables the use of 22-gauge needles with tissue adequacy rates comparable to 19-gauge needles, while reducing blood contamination. 2. This technique may be particularly beneficial for patients with challenging anatomies or high risk of adverse events, providing a safer and equally effective alternative to traditional biopsy approaches. 3. The adoption of HST could expand the indications and applicability of EUS-LB, making it a more versatile and patient-centered diagnostic tool.

HBV Genotype and Biomarkers Predict Severe Flares After NA Cessation

The study highlights the significant role of HBV genotype and end-of-treatment (EOT) biomarkers in predicting severe virologic relapses (SVRel) and severe biochemical flares (SBF) after nucleos(t)ide analogue (NA) cessation in patients with chronic hepatitis B virus (HBV) infection. Here's a detailed breakdown of the findings: ### HBV Genotype and Treatment Response: 1. **Genotype Influence**: - Different HBV genotypes were associated with varying risks of SVRel and SBF. - Genotypes C, D, and E were linked to higher rates of relapse and flares. - Notably, none of the patients with genotype A developed severe biochemical flares (SBF), indicating a potentially protective role of genotype A against severe post-cessation events. 2. **Genotype as a Predictive Marker**: - Non-A genotypes were significantly associated with a higher risk of severe biochemical flares (SBF) after NA cessation. This was supported by a multivariate analysis, where non-A genotype had an adjusted odds ratio (aOR) of 19.03 (p=0.018) for predicting SBF. ### Biomarkers and Predictive Value: 1. **Key Biomarkers**: - HBcrAg (Hepatitis B core-related antigen): Detectable levels at the end of treatment were strongly associated with severe virologic relapses (SVRel). The adjusted odds ratio (aOR) for SVRel was 3.93 (p=0.01). - HBV RNA: Detectable HBV RNA was independently predictive of severe biochemical flares (SBF) with an aOR of 7.84 (p=0.005). - Anti-HBc IgG: Lower levels of anti-HBc IgG were associated with a higher risk of SBF (aOR 0.31, p=0.016). 2. **COBRA Score**: - A risk stratification tool, called the COBRA score, was developed using three biomarkers: HBcrAg, HBV RNA, and anti-HBc IgG. - A COBRA score ≥2 was effective in identifying patients at increased risk for severe biochemical flares (SBF), with a sensitivity of 80.0% and a negative predictive value (NPV) of 90.7%. ### Conclusion of the Study: - The study concludes that both HBV genotype and EOT biomarkers (HBcrAg, HBV RNA, and anti-HBc IgG) are valuable predictors of severe virologic relapses (SVRel) and severe biochemical flares (SBF) after NA cessation in patients with chronic HBV infections. - Among the genotypes, non-A genotypes (C, D, and E) were associated with higher risks of severe events, whereas genotype A appeared to confer a lower risk of SBF. - The COBRA score provides a practical tool for individualized risk stratification, enabling clinicians to identify patients at the highest risk and tailor post-cessation monitoring and management strategies accordingly. These findings underscore the importance of incorporating genotype and biomarker assessments into clinical decision-making to improve patient outcomes when discontinuing NA therapy in chronic HBV management.

The hepatitis B vaccine—the first anti-cancer vaccine (Lancet Gastro Hepato 2026)

The hepatitis B vaccine, often hailed as the first anti-cancer vaccine, represents a groundbreaking achievement in global public health. Chronic hepatitis B virus (HBV) infection is a leading cause of hepatocellular carcinoma (HCC), a deadly form of liver cancer. By preventing HBV infection, the vaccine directly reduces the risk of HCC, making it a powerful tool in cancer prevention. Since its introduction, the hepatitis B vaccine has significantly reduced HBV infection rates worldwide, particularly in regions with historically high prevalence, such as Southeast Asia. This region has long borne the brunt of HBV-related diseases, with millions suffering from chronic infections and liver-related complications. Universal vaccination programs, especially those targeting newborns and infants, have been instrumental in curbing HBV transmission from mother to child, one of the primary modes of infection. The vaccine's impact is profound—countries with high vaccination coverage have reported dramatic declines in HBV prevalence and HCC incidence among younger generations. For example, in Taiwan, a pioneer in HBV vaccination, the incidence of childhood HCC has nearly been eradicated. As global vaccination efforts expand, the hepatitis B vaccine continues to save millions of lives, offering hope for a future free from HBV and its devastating consequences, including liver cancer.

Rat Hepatitis E - J of Hepatology-Jan.26

Rat Hepatitis E (rHEV), also known as Rocahepevirus ratti, is an emerging zoonotic pathogen that has garnered significant attention in recent years due to its potential to infect humans and cause clinical disease. It was first identified in wild rats in Germany in 2009 and has since been detected in rodents and other small mammals across the globe. Although it was initially believed to be confined to rodents, subsequent studies have revealed its zoonotic potential, with confirmed human cases reported in multiple countries. ### Differences Between Rat Hepatitis E (rHEV) and Human Hepatitis E (HEV) Human Hepatitis E is primarily caused by the Paslahepevirus balayani genus, which includes genotypes HEV-1 to HEV-4. In contrast, Rat Hepatitis E belongs to the Rocahepevirus genus. While both viruses share structural similarities, including a ~7 kb positive-sense single-stranded RNA genome organized into four open reading frames (ORFs), they differ significantly in genetic composition. rHEV shares only about 50–60% nucleotide identity with human HEV, making it genetically distinct. Key differences include: 1. **Host Range**: - Human HEV (HEV-1 to HEV-4) primarily infects humans, pigs, and other animals. - rHEV was initially thought to be rodent-specific but has now been shown to infect humans as well, indicating its zoonotic potential. 2. **Genomic Differences**: - Despite structural similarities, rHEV exhibits significant genetic divergence from human HEV, particularly in nucleotide sequences. 3. **Diagnostic Challenges**: - Routine hepatitis E diagnostics often fail to detect rHEV infections, as they are designed for Paslahepevirus. Diagnosis of rHEV requires specialized pan-hepevirus PCR assays, highlighting the limitations of current diagnostic methods. 4. **Clinical Presentation**: - Human HEV infections can cause a spectrum of disease ranging from asymptomatic to severe acute hepatitis, particularly in pregnant women and immunocompromised individuals. - rHEV infections in humans have also shown a wide range of clinical manifestations, from asymptomatic cases to severe acute and chronic hepatitis. Extrahepatic complications, such as acute renal failure, glomerulonephritis, acute pancreatitis, and meningoencephalitis, have also been reported. ### Clinical Impact of Rat Hepatitis E The emergence of rHEV as a zoonotic pathogen raises several important clinical and public health concerns: 1. **Human Cases**: - Since the first human case of rHEV was identified in 2017 in a liver transplant recipient in Hong Kong, a total of 48 human infections have been reported across Hong Kong, Spain, mainland China, France, Germany, and Canada. These cases involved individuals of both sexes and a wide age range (7–89 years). 2. **Chronic Hepatitis**: - Chronic hepatitis, which can potentially progress to cirrhosis, has been observed in immunocompromised individuals infected with rHEV. In the Hong Kong cohort, 12 out of 22 identified cases developed chronic hepatitis. 3. **Treatment**: - No virus-specific therapies are currently available for rHEV. However, ribavirin, a drug commonly used to treat human HEV infections, has shown efficacy in some rHEV cases. 4. **Extrahepatic Manifestations**: - rHEV infections have been associated with severe complications beyond the liver, including acute renal failure, glomerulonephritis, acute pancreatitis, and meningoencephalitis. 5. **Global Circulation**: - Phylogenetic analyses suggest that rHEV strains are circulating globally, likely facilitated by the movement of rodents or contaminated materials. Strains from a single geographic region do not always form monophyletic groups, indicating ongoing global transmission. ### Future Clinical and Public Health Implications 1. **Zoonotic Risk**: - rHEV's ability to infect humans without requiring major genetic changes underscores its zoonotic potential. Broader genomic surveillance in both human and animal populations is essential to better understand transmission routes and zoonotic risks. 2. **Diagnostic Improvements**: - Incorporating rHEV-specific assays into routine diagnostic protocols for unexplained hepatitis is critical to identifying and managing cases. This approach has already proven effective in Hong Kong, where 22 human cases were identified over seven years. 3. **Evolutionary Insights**: - Molecular clock analyses suggest that rHEV originated a few hundred years ago, with some strains circulating in rodents and potentially humans for decades before being recognized. Understanding its evolutionary history can help distinguish between newly emerging threats and long-standing but overlooked pathogens. 4. **Molecular Adaptation**: - Studies indicate that rHEV is well-adapted to human hosts, with codon usage patterns and selective pressures suggesting that most rHEV lineages possess the translational capacity to replicate efficiently in human cells. Ongoing research is needed to identify molecular adaptations that facilitate cross-species transmission. 5. **Surveillance and Public Health Strategies**: - Expanding genomic surveillance and developing standardized classification systems, such as the open-access tool created by researchers, will enable better tracking of rHEV strains and their public health impact. Enhanced surveillance will also help identify genetic determinants of human adaptation and monitor the emergence of new strains. 6. **Infection Prevention**: - As rodents are the primary reservoir for rHEV, controlling rodent populations and minimizing human exposure to contaminated environments are crucial for preventing infections. ### Conclusion Rat Hepatitis E (rHEV) is an emerging zoonotic pathogen with significant clinical and public health implications. While it shares some similarities with human HEV, its genetic distinctiveness and zoonotic potential make it a unique public health concern. The identification of human cases, particularly in immunocompromised individuals, highlights the need for improved diagnostic tools, expanded surveillance, and further research into its transmission dynamics and molecular adaptations. Understanding the full extent of rHEV's impact will be critical for anticipating future risks and developing effective prevention and treatment strategies.

HBsAg, HBeAg and HCC prediction

HBsAg (Hepatitis B surface antigen) and HBeAg (Hepatitis B e antigen) are important biomarkers in understanding the progression and risk factors of chronic hepatitis B virus (HBV) infection, particularly in relation to hepatocellular carcinoma (HCC) prediction. ### HBeAg and HCC Risk: HBeAg status is a key indicator of the phase of chronic HBV infection. HBeAg-positive patients generally have higher HBV DNA levels and an increased risk of HCC compared to HBeAg-negative patients. However, the relationship between HBV DNA levels and HCC risk differs based on HBeAg status: - For **HBeAg-negative patients**, HCC risk increases with higher HBV DNA levels, plateauing at ≥5 log10 IU/mL. - For **HBeAg-positive patients**, the association between HBV DNA levels and HCC risk is less pronounced. ### HBsAg and HCC Risk: HBsAg levels provide additional insight into HCC risk: - In **HBeAg-negative patients**, high HBsAg levels (≥1000 IU/mL) are associated with increased HCC risk. - In **HBeAg-positive patients**, a reverse association is observed. High HBsAg levels (≥10,000 IU/mL) are linked to a lower risk of HCC, particularly in the immune-tolerant phase. ### Immune-Tolerant Phase and HCC: Patients in the immune-tolerant phase (defined by HBeAg positivity, high HBV DNA, normal ALT, and no significant fibrosis) generally have a low short-term HCC risk. However, HCC risk increases over time due to factors like aging, phase transitions, or declining HBsAg levels. Long-term monitoring is essential, as a drop in HBsAg levels or a phase transition significantly elevates HCC risk. ### Clinical Implications: - Patients with HBeAg positivity and HBsAg levels ≥10,000 IU/mL are considered genuinely immune-tolerant and have a lower HCC risk. Those with lower HBsAg levels (<10,000 IU/mL) may have a higher risk and require closer monitoring or antiviral treatment. - Dynamic monitoring, rather than relying solely on baseline characteristics, is crucial to account for the fluctuating nature of chronic HBV infection. Factors like age, fibrosis, family history of HCC, and metabolic conditions (e.g., diabetes) should also inform risk stratification and treatment decisions. In summary, HBsAg and HBeAg levels, along with other clinical factors, play a critical role in predicting HCC risk and guiding management strategies for patients with chronic HBV.

Large-Scale Profiling of HBsAg Levels in Chronic Hepatitis B for Functional Cure Development

The large-scale profiling of hepatitis B surface antigen (HBsAg) levels in patients with chronic hepatitis B (CHB) is a critical area of research aimed at advancing the development of therapies for achieving a functional cure. This study focused on quantitative hepatitis B surface antigen (qHBsAg) profiles, which serve as a key biomarker for understanding viral transcriptional activity and immune control in CHB patients. ### Key Findings: 1. **Baseline qHBsAg Levels**: - Most patients with CHB exhibited relatively low qHBsAg levels at baseline, indicating limited viral activity and some degree of immune control. - However, a significant proportion of patients had persistently high qHBsAg levels, suggesting ongoing viral replication and insufficient immune-mediated control. 2. **Longitudinal Trends**: - qHBsAg levels generally declined very slowly over time, reflecting the indolent nature of antigen loss during chronic infection. - Only a minority of patients achieved HBsAg seroclearance (complete loss of the surface antigen) during long-term follow-up, highlighting the challenges in achieving spontaneous functional cure. 3. **Clinical Predictors of HBsAg Seroclearance**: - Certain factors were associated with lower qHBsAg levels and a greater likelihood of seroclearance: - Older age. - Absence of hepatitis B e antigen (HBeAg). - Lower levels of viral replication. - Higher alanine aminotransferase (ALT) levels relative to qHBsAg levels, which may indicate immune activity against the virus. ### Implications for Functional Cure Development: - **Challenges in Achieving Functional Cure**: - Many CHB patients have qHBsAg profiles that make spontaneous functional cure unlikely. This includes patients with high antigen burdens, who are less likely to respond to current or emerging antiviral treatments. - The slow decline in qHBsAg levels over time underscores the need for therapies that can accelerate antigen loss and improve immune control. - **Stratification of Patients**: - qHBsAg levels can be used to stratify patients based on their likelihood of achieving seroclearance and their responsiveness to treatment. This biomarker provides valuable insights for tailoring therapeutic approaches. - **Drug Development Considerations**: - The study emphasizes the importance of accounting for baseline qHBsAg heterogeneity when designing novel therapies. Patients with high antigen burdens may require more potent or combination therapies to achieve functional cure. - Emerging antiviral strategies should focus on targeting persistent viral activity and enhancing immune-mediated control in patients with high qHBsAg levels. ### Conclusion: This research underscores the importance of large-scale profiling of qHBsAg levels in CHB patients to better understand the dynamics of antigen loss and to inform the development of more effective therapies. By identifying clinical predictors of seroclearance and highlighting the challenges posed by high antigen burdens, the study provides a roadmap for advancing therapeutic strategies aimed at achieving a functional cure for CHB.

STASH Trial

The **STASH trial** (Short for "Steroid Tapering in Severe Alcohol-associated Hepatitis") was a multicenter, open-label randomized clinical trial aimed at evaluating the efficacy and safety of a tapered prednisolone regimen compared to the standard fixed-dose regimen in patients with **severe alcohol-associated hepatitis (AAH)**. The trial was conducted to address concerns about the high risk of infections associated with corticosteroid treatment in AAH patients, while still preserving its therapeutic benefits. ### Background: Severe AAH is a life-threatening condition characterized by liver inflammation due to excessive alcohol consumption. Corticosteroids, such as prednisolone, are the standard treatment for severe AAH because they reduce liver inflammation and improve short-term survival. However, corticosteroids suppress the immune system, leading to a high risk of **secondary infections**, which can worsen patient outcomes. Clinical guidelines recommend a fixed daily dose of **40 mg prednisolone for 28 days**, but there has been ongoing debate about whether a tapering regimen could reduce infection risks while maintaining efficacy. ### Study Design: - **Study Period**: March 2023 to August 2024. - **Participants**: 254 adults diagnosed with severe AAH. - **Intervention Groups**: 1. **Fixed-dose group**: Participants received 40 mg/day of prednisolone for 28 days (standard regimen). 2. **Tapered-dose group**: Participants received a four-week tapering regimen of prednisolone (gradual dose reduction over 28 days). - **Primary Endpoint**: Incidence of infections by day 90, assessed using standardized criteria. - **Secondary Endpoints**: Mortality at day 90, transplant-free survival, liver function improvement (measured by MELD score), rates of acute kidney injury (AKI), and overall adverse events. ### Key Findings: 1. **Infection Risk**: - Tapered-dose group had significantly fewer infections by day 90 compared to the fixed-dose group (**19.7% vs. 33.1%**). - Microbiologically confirmed infections were also reduced in the tapered-dose group. - The most common infections were lung infections, followed by urinary and peritoneal infections. 2. **Mortality and Survival**: - Despite the reduction in infection rates, there was **no significant difference in day-90 mortality** or transplant-free survival between the two groups. 3. **Liver Function and AKI**: - Both groups showed similar improvements in liver function (MELD score) and comparable rates of acute kidney injury. 4. **Adverse Events**: - Overall adverse events and hospitalizations were more frequent in the fixed-dose group, suggesting a safety advantage with the tapering regimen. ### Conclusion: The STASH trial demonstrated that a **tapered prednisolone regimen significantly reduces the risk of infections** in patients with severe AAH compared to the standard fixed-dose regimen. Importantly, this reduction in infection risk was achieved **without compromising short-term survival** or liver function improvement. These findings suggest that tapering corticosteroids is a safer and more effective strategy for managing severe AAH, addressing the long-standing challenge of balancing immunosuppression with infection risk. ### Implications: The results of the STASH trial could lead to a revision of current clinical guidelines for the treatment of severe AAH, favoring a tapered prednisolone regimen over the fixed-dose approach. This approach may improve patient safety and outcomes by minimizing secondary infections, which are a major cause of morbidity and mortality in this population.

Zetomipzomib and the PORTOLA Trial

Zetomipzomib and the PORTOLA Trial represent a significant advancement in the treatment of autoimmune hepatitis (AIH), particularly for patients who are inadequately controlled on standard therapies like steroids and azathioprine. Below is a detailed explanation of both Zetomipzomib and the PORTOLA trial: ### **Zetomipzomib (KZR-616):** Zetomipzomib is a groundbreaking, first-in-class selective immunoproteasome inhibitor. Unlike conventional proteasome inhibitors typically used in oncology, zetomipzomib specifically targets the immunoproteasome subunits **LMP7** and **LMP2**. These subunits are primarily active in immune cells, such as activated T cells, B cells, and antigen-presenting cells, which are crucial players in autoimmune diseases like AIH. #### **Mechanism of Action:** By selectively inhibiting the immunoproteasome, zetomipzomib works in the following ways: 1. **Reduces presentation of autoantigens:** This limits the immune system's ability to attack self-tissues. 2. **Downregulates pathogenic Th1/Th17 responses:** These responses are known to drive inflammation and tissue damage in autoimmune diseases. 3. **Restores regulatory immune balance:** It promotes immune homeostasis without causing broad immunosuppression, which minimizes the risk of infections and other complications associated with traditional immunosuppressive therapies. This mechanism positions zetomipzomib as a promising alternative to conventional therapies, potentially reducing the toxicities and side effects associated with steroids and azathioprine. --- ### **The PORTOLA Phase 2a Trial:** The PORTOLA trial is the first clinical study to evaluate zetomipzomib in patients with autoimmune hepatitis who have not responded adequately to standard therapy. This trial is a critical step in understanding the drug's efficacy and safety in this difficult-to-treat patient population. #### **Key Features of the PORTOLA Trial:** 1. **Open-label, multi-center design:** The trial involves multiple research centers and does not use a placebo control, allowing all participants to receive zetomipzomib. 2. **Subcutaneous weekly dosing:** Zetomipzomib is administered via weekly subcutaneous injections, which is a convenient and patient-friendly approach. 3. **Inclusion criteria:** The trial specifically targets patients with persistent elevations in liver enzymes (ALT/AST) despite ongoing immunosuppressive therapy. --- ### **Emerging Clinical Outcomes:** Preliminary results from the PORTOLA trial (expected to be fully presented in 2024–2025) demonstrate significant promise for zetomipzomib in AIH management: 1. **Improvements in liver enzyme levels:** Many patients experienced meaningful reductions in ALT and AST levels, indicating improved liver function. 2. **Reduction in IgG levels:** Elevated IgG is a hallmark of AIH, and its reduction suggests a decrease in disease activity. 3. **Steroid-sparing effects:** Several patients were able to reduce their steroid requirements while maintaining or improving disease control. 4. **Biochemical remission or near-remission:** Some patients achieved biochemical remission or near-remission, even while tapering conventional immunosuppressive drugs. 5. **Tolerability:** Zetomipzomib was generally well-tolerated, with mild adverse effects such as fatigue, injection-site reactions, and transient gastrointestinal symptoms. These findings suggest that zetomipzomib could address unmet needs in AIH, particularly for patients who experience disease flares or side effects from current therapies. --- ### **Why This Matters for AIH:** Autoimmune hepatitis is a chronic condition that often requires long-term immunosuppression, with many patients experiencing treatment challenges due to side effects or incomplete responses to standard drugs. Zetomipzomib offers a novel, targeted approach to modulating the immune system, addressing the core pathophysiology of the disease. If larger studies confirm the PORTOLA trial's findings, zetomipzomib could become: 1. **A steroid-sparing option:** Reducing the reliance on corticosteroids and their associated toxicities. 2. **A therapy for incomplete responders:** Providing a solution for patients whose disease remains active despite standard treatments. 3. **A mechanistically novel treatment:** As the first major innovation in AIH pharmacotherapy in decades, zetomipzomib could redefine how the disease is managed. Overall, zetomipzomib and the PORTOLA trial represent a promising step forward in improving outcomes for patients with autoimmune hepatitis, particularly those with difficult-to-treat disease.

Redefining PSC Care

Redefining care for Primary Sclerosing Cholangitis (PSC) requires a comprehensive, patient-centered approach that integrates modern strategies for symptom management, disease progression monitoring, and quality-of-life improvements. PSC is a chronic liver disease with significant unmet needs, including severe symptoms, high cancer risks, and limited therapeutic options. Below is a detailed breakdown of how PSC care is being redefined: ### 1. **Symptom Management: Addressing Quality-of-Life Concerns** - **Pruritus (Itching):** Pruritus is one of the most common and debilitating symptoms of PSC, affecting about 50% of patients, with 30% experiencing moderate-to-severe itching. Despite the widespread use of treatments like bile acid sequestrants (36%), hydroxyzine (23%), rifampicin (17%), and naltrexone (14%), many of these therapies have limited efficacy. - **Call for Better Therapies:** There is an urgent need for safe, effective, and long-term antipruritic medications. The FITCH trial demonstrated promising results with bezafibrate, which improved pruritus by at least 50% in 41% of patients compared to 11% in the placebo group. - **Patient Priorities:** Symptom relief, particularly pruritus, is a top motivator for patients joining drug trials, highlighting the importance of addressing quality-of-life symptoms in care strategies. ### 2. **Structured Surveillance and Monitoring** - **Scheduled ERCP Follow-Up:** Regularly scheduled ERCP (endoscopic retrograde cholangiopancreatography) interventions have been shown to improve long-term transplant-free survival and reduce infections compared to on-demand procedures. The low complication rate (4%) ensures safety when the procedure is performed in a structured, protocolized manner. - **Routine MRCP Surveillance:** Magnetic resonance cholangiopancreatography (MRCP) allows earlier detection of dominant strictures and cholangiocarcinoma, which leads to better survival outcomes. Routine MRCP reduces the risk of death by 73.8% compared to symptom-triggered imaging (HR 0.9, p < 0.001). This proactive approach identifies disease progression earlier and enables timely interventions. - **Stricture-Driven Management:** The benefits of MRCP surveillance come from proactive management of biliary strictures rather than relying solely on late detection of hepatic malignancies. ### 3. **Patient Involvement in Research** - **Engagement Gap:** While 61% of patients are willing to participate in clinical trials, only 26% have been asked, highlighting a significant gap in patient engagement and recruitment. - **Patient Motivation:** Pruritus relief is the top motivator for PSC patients joining drug trials, emphasizing the need for trials focused on quality-of-life improvements and symptom control. - **Future Directions:** Greater inclusion of patient-reported outcome measures in research and therapeutic development is essential for personalized care. ### 4. **Cancer Screening and Risk Management** - **High Cancer Risk:** PSC remains a progressive disease with a high risk for hepatobiliary and colorectal cancers. Surveillance strategies like MRCP and ERCP are critical for early detection of cholangiocarcinoma and dominant strictures. - **Earlier Detection Advantage:** Routine imaging allows for timely interventions that improve survival outcomes. ### 5. **Modern Therapeutic Development** - **Personalized Care:** Future PSC care will emphasize personalized, high-quality ambulatory hepatology care tailored to individual patient needs. - **ABCDE Model:** A stepwise PSC care strategy includes: - **A**wareness: Educating patients about PSC and its risks. - **B**ile ducts: Monitoring and managing strictures and infections. - **C**ancer: Screening for hepatobiliary and colorectal cancers. - **D**isability: Addressing quality-of-life symptoms like pruritus and fatigue. - **E**xplore trials: Encouraging participation in clinical trials to advance treatment options. ### 6. **Improved Disease Management** - **Long-Term ERCP Follow-Up:** Regular ERCP interventions help identify disease progression earlier and reduce recurrent cholangitis episodes, improving transplant-free survival. - **State-of-the-Art Review Findings:** Modern care strategies focus on halting disease progression and improving life quality through symptom control, structured surveillance, and personalized treatment approaches. ### 7. **Conclusion: Redefining PSC Care** Redefining PSC care involves combining early symptom-focused interventions, structured surveillance (MRCP/ERCP), and personalized treatment approaches. This integrated strategy targets both halting disease progression and improving patient quality of life. The urgent need for effective antipruritic therapies, better patient engagement in research, and proactive cancer screening further underscores the importance of modernizing PSC care. By addressing unmet needs and leveraging advancements in monitoring and therapeutic development, PSC care can significantly improve long-term outcomes and provide patients with a better quality of life.

Treatment of Chronic Hepatitis B - AASLD/IDSA Guideline 2025

As of my knowledge cutoff in October 2023, the most recent guidelines for the treatment of chronic hepatitis B (CHB) were published by the American Association for the Study of Liver Diseases (AASLD) and the Infectious Diseases Society of America (IDSA). While I cannot provide details on a "2025 guideline," I can summarize the key recommendations from the most recent guidance available, which may still be relevant in 2025 unless updated guidelines have been released. ### Key Recommendations from the AASLD Guidelines for CHB Management #### 1. **Phases of Chronic Hepatitis B** - Chronic hepatitis B is categorized into five disease phases: 1. *Immune-tolerant phase*: High HBV DNA levels, normal ALT, minimal liver damage. 2. *Immune-active phase (HBeAg-positive or HBeAg-negative)*: Elevated ALT, active liver inflammation, and high HBV DNA. 3. *Inactive carrier phase*: Low HBV DNA, normal ALT, minimal liver inflammation. 4. *HBsAg-negative clearance phase*: HBsAg loss with anti-HBs development. 5. *Indeterminate phase*: Patients who do not clearly fit into the above phases. - Management strategies are tailored to the patient’s disease phase, ALT levels, HBV DNA levels, and liver fibrosis status. #### 2. **Preferred Antiviral Therapies** - First-line oral antiviral agents include: - **Entecavir (ETV)** - **Tenofovir disoproxil fumarate (TDF)** - **Tenofovir alafenamide (TAF)** - These drugs are highly effective and have a high barrier to resistance, making them the preferred choices for long-term HBV suppression. #### 3. **Treatment for Specific Populations** - **Immune-Tolerant Phase**: - Antiviral therapy is recommended for patients over 40 years old or those with significant liver inflammation or fibrosis (≥F2). - **Indeterminate Phase**: - Treatment decisions should be individualized for HBeAg-negative patients without cirrhosis who fall into the "grey zone" of unclear disease activity. Shared decision-making is emphasized. - **Pregnancy**: - For HBsAg-positive pregnant women with HBV DNA >200,000 IU/mL, initiate TDF or TAF at 28 weeks of gestation to prevent mother-to-child transmission. - **Breastfeeding**: - TDF and TAF are considered safe during breastfeeding due to minimal drug transfer into breast milk. #### 4. **Antiviral Discontinuation** - Nucleos(t)ide analog (NA) therapy should not be stopped unless HBsAg loss (functional cure) is achieved, as discontinuation otherwise poses a risk of HBV relapse or flare. - If therapy is discontinued, close monitoring of ALT and HBV DNA levels is required every 1–3 months for the first 6 months, then quarterly for the next year. #### 5. **Functional Cure** - The ultimate goal of therapy is achieving HBsAg loss (functional cure). However, this outcome is rare with current therapies and is more commonly achieved with interferon-based treatments than with nucleos(t)ide analogs. #### 6. **Fibrosis Assessment** - Non-invasive tools such as transient elastography (FibroScan) and FIB-4 are recommended for evaluating liver fibrosis and determining the need for treatment. #### 7. **Surveillance for Hepatocellular Carcinoma (HCC)** - High-risk groups require lifelong HCC surveillance with semiannual ultrasound ± alpha-fetoprotein (AFP) testing. These groups include: - Patients with cirrhosis. - Males over 40 years and females over 50 years. - Patients with a family history of HCC. - Patients co-infected with HBV and HIV or hepatitis D virus (HDV). #### 8. **Prevention of HBV Transmission** - Antiviral therapy should be considered for HBsAg-positive individuals at high risk of transmitting HBV (e.g., healthcare workers, sexual partners). - Universal HBV vaccination is recommended for all adults aged 19–59 years and all infants. #### 9. **HBV-HIV and HBV-HDV Coinfection** - Patients co-infected with HBV and HDV or HIV should undergo regular HCC surveillance regardless of their liver fibrosis status. #### 10. **Research Gaps and Future Directions** - The AASLD has identified key research priorities, including: - Developing better biomarkers for disease activity and treatment response (e.g., HBsAg quantitation, HBcrAg, HBV RNA). - Exploring new strategies for achieving a functional cure. - Addressing management of patients in the indeterminate phase. - Future updates to the guidelines are planned as new therapies and diagnostic tools are approved by the FDA. #### 11. **Shared Decision-Making** - Patient preferences, ability to adhere to treatment, and access to therapy should guide decisions on initiating, continuing, or discontinuing treatment. #### 12. **Alignment with WHO Goals** - The AASLD supports the World Health Organization’s (WHO) initiative to simplify HBV treatment criteria, but retains phase-based thresholds for high-resource settings. --- ### Conclusion The AASLD/IDSA guidelines emphasize individualized care, evidence-based recommendations, and shared decision-making in the management of chronic hepatitis B. First-line antiviral therapies (ETV, TDF, TAF) are effective for long-term viral suppression, and treatment strategies are tailored to the patient’s disease phase, age, and comorbidities. Prevention of HBV transmission, including vaccination and antiviral prophylaxis in high-risk populations, remains a cornerstone of public health efforts. Ongoing research and future updates will likely focus on achieving functional cures and improving diagnostic and treatment approaches. If you are specifically looking for the 2025 guideline, I recommend checking the AASLD or IDSA websites for the latest updates and publications.

Secondary Iron Overload and the Liver

Secondary iron overload is more common than hereditary hemochromatosis and arises from conditions such as transfusions, ineffective erythropoiesis, and chronic liver diseases. Iron absorption is regulated by hepcidin, which suppresses ferroportin when iron levels are high, reducing plasma iron entry. Diagnosing iron overload involves assessing transferrin saturation (TSAT >45%) and ferritin levels, though ferritin can be elevated due to inflammation or malignancy. Non-invasive imaging, particularly MRI, is preferred for measuring liver iron content, as it correlates well with biopsy results. Secondary iron overload is linked to various conditions, including iron-loading anemias (e.g., thalassemia, myelodysplastic syndromes, sickle cell disease) and chronic liver diseases (e.g., non-alcoholic fatty liver disease [NAFLD], alcoholic liver disease [ALD], viral hepatitis). Thalassemia is a leading cause due to frequent transfusions and suppressed hepcidin, with risks of fibrosis, cirrhosis, and hepatocellular carcinoma (HCC). NAFLD and ALD are also associated with iron overload, contributing to worse outcomes and advanced fibrosis. Hepatitis C virus (HCV) suppresses hepcidin, increasing iron absorption, while hepatitis B virus (HBV) with HDV co-infection correlates with advanced fibrosis. Treatment depends on the cause: phlebotomy for hereditary hemochromatosis and post-transplant cases without anemia, and iron chelators for transfusion-dependent conditions like thalassemia. No proven therapies currently exist for NAFLD-, hepatitis-, or ALD-related iron overload.

Cardiac Syndromes in Liver Disease

Cardiac syndromes in liver disease encompass a spectrum of complex interactions between the heart and liver, with both organs mutually influencing each other. These syndromes include congestive hepatopathy (CH), cardiogenic liver injury (CLI), cirrhotic cardiomyopathy (CCM), hepatopulmonary syndrome (HPS), and portopulmonary hypertension (PoPH). Below is a detailed explanation of these syndromes and their management: --- ### 1. **Congestive Hepatopathy (CH)** #### **Pathophysiology**: - CH occurs due to **long-standing venous congestion** from chronic heart failure, affecting 15–65% of heart-failure patients. - Mechanisms include **backward transmission of right-atrial pressure**, **cholestasis**, **microthrombi**, and **hypoxic injury**, which contribute to hepatic fibrosis. #### **Clinical Presentation**: - CH is often **asymptomatic**, with mild elevation of liver enzymes (AST/ALT <3× upper limit) and cholestatic patterns. - **Ascites** may develop in ~25% of patients. #### **Management**: - Focuses on **optimizing heart function**: - **Diuretics** to manage fluid overload. - **Treatment of tricuspid regurgitation**. - **Sacubitril/valsartan** to improve heart failure outcomes. - Prognostic tools like **MELD-XI scores** and hepatic fibrosis scores are used in heart-failure and transplant candidates. --- ### 2. **Cardiogenic Liver Injury (CLI)** #### **Pathophysiology**: - CLI is an **acute liver injury** caused by **sudden hypoperfusion** combined with **venous stasis**, occurring in 20–30% of acute heart-failure cases. #### **Clinical Presentation**: - **Dramatic lab changes**: - AST/ALT and LDH levels rise >20× within days. - ALT/LDH ratio <1.5 strongly suggests **hypoxic hepatitis**. #### **Management**: - Immediate correction of **cardiac/respiratory failure**. - Use of **norepinephrine** for shock and **dobutamine** for inotropy. - Early mechanical support (e.g., ECMO or ventricular assist devices) when needed. #### **Prognosis**: - CLI has a **serious prognosis**, with high mortality risk even after enzyme normalization. - Worse outcomes are associated with **encephalopathy** or **high phosphate levels**. --- ### 3. **Cirrhotic Cardiomyopathy (CCM)** #### **Pathophysiology**: - CCM is a **cardiac dysfunction** specific to cirrhosis, occurring despite the absence of prior heart disease. Prevalence ranges from 26–81%. - Mechanisms include **hyperdynamic circulation**, **inflammation**, **autonomic dysfunction**, and **myocardial remodeling**. #### **Diagnostic Criteria** (Updated in 2020): - **Systolic dysfunction**: LVEF ≤50% or GLS <18%. - **Diastolic dysfunction**: ≥3 echocardiographic abnormalities (e.g., E/A ratio, deceleration time, E/e′ ratio). #### **Management**: - Evidence is limited; management focuses on: - **Volume control** with diuretics. - **Natriuretic-dose spironolactone**. - **Cautious use of beta-blockers**. - **Sodium restriction**. --- ### 4. **Hepatopulmonary Syndrome (HPS)** #### **Pathophysiology**: - HPS occurs in ~25% of cirrhotic patients and is defined by **liver disease**, **intrapulmonary vasodilation**, and **hypoxemia**. #### **Diagnosis**: - Confirmed through **contrast-enhanced transthoracic echocardiography (CE-TTE)**, showing delayed microbubble appearance. - **PaO2 <70 mmHg** with widened alveolar–arterial (A–a) gradient supports the diagnosis. #### **Management**: - No effective medical therapy exists. - **Oxygen supplementation** for PaO2 <60 mmHg. - **Liver transplantation (LT)** is the only curative option. --- ### 5. **Portopulmonary Hypertension (PoPH)** #### **Pathophysiology**: - PoPH occurs in ~2–6% of patients with portal hypertension. - It requires **right-heart catheterization** for definitive diagnosis. #### **Management**: - Based on **pulmonary arterial hypertension (PAH) therapies**: - **Endothelin receptor antagonists (ERA)**. - **Phosphodiesterase-5 (PDE-5) inhibitors**. - **Prostacyclin analogs**. - **Macitentan** showed improvement in pulmonary vascular resistance (PVR) in the **PORTICO trial**. --- ### 6. **Atrial Fibrillation (AF) and Liver Disease** #### **Management Considerations**: - **Non-vitamin K antagonist oral anticoagulants (NOACs)** are preferred over warfarin in **Child-Pugh A/B** patients. - Avoid NOACs in **Child-Pugh class C** due to high bleeding risk. - Individualized decision-making is essential. --- ### Summary Cardiac syndromes in liver disease represent a challenging interplay between cardiac and hepatic dysfunction. These conditions require careful diagnosis and management, as they often have overlapping symptoms and mechanisms. Optimizing heart function, addressing liver-specific complications, and considering transplantation are key strategies in improving outcomes. Detailed prognostic tools, advanced imaging, and targeted therapies are critical for managing these complex syndromes effectively.